Clinical Trial Update: Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza [Phase 1]

View source ↗

Summary

Phase 1 blinded cross-over bioequivalence trial comparing Luitpold azacitidine with Vidaza has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Chronic Myeloid Leukemia
• Myelodysplastic Syndrome
• Myelofibrosis

Drugs mentioned

• Luitpold Azacitidine (azacitidine)
• VIDAZA (AZACITIDINE)

Snippet

Sponsor: American Regent, Inc. | Conditions: Myelodysplastic Syndrome, Myelofibrosis | Phase 1 | Status: COMPLETED | Results posted: 2025-05-25